Free Trial
NASDAQ:NRBO

NeuroBo Pharmaceuticals (NRBO) Stock Price, News & Analysis

NeuroBo Pharmaceuticals logo
$0.85 +0.04 (+4.55%)
As of 04/24/2025

About NeuroBo Pharmaceuticals Stock (NASDAQ:NRBO)

Key Stats

Today's Range
$0.76
$0.86
50-Day Range
$0.73
$1.84
52-Week Range
$2.08
$5.30
Volume
202,481 shs
Average Volume
48,742 shs
Market Capitalization
$7.32 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00
Consensus Rating
Buy

Company Overview

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene. NeuroBo Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.

Receive NRBO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NeuroBo Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

NRBO Stock News Headlines

2025 could be "worse than the dot-com bust", says man who predicted 2008 banking crisis
What's coming next to the U.S. market could be worse than anything we've ever seen before – worse than the dot-com bust, worse than the COVID crash, and even worse than the Great Depression. What's coming, he says, could soon crash the market by 50% or more – and keep it down for 10, 20, or even 30 years.
NeuroBo Pharmaceuticals Rebrands Amidst Strategic Changes
NeuroBo Pharmaceuticals announces relignment, change name
See More Headlines

NRBO Stock Analysis - Frequently Asked Questions

NeuroBo Pharmaceuticals' stock was trading at $2.03 at the beginning of the year. Since then, NRBO stock has decreased by 58.1% and is now trading at $0.85.
View the best growth stocks for 2025 here
.

NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) posted its earnings results on Thursday, November, 7th. The company reported ($0.55) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.82) by $0.27.

NeuroBo Pharmaceuticals's stock reverse split before market open on Thursday, December 21st 2023. The 1-8 reverse split was announced on Thursday, December 21st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, December 21st 2023. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

Shares of NRBO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that NeuroBo Pharmaceuticals investors own include Meta Platforms (META), NVIDIA (NVDA), Broadcom (AVGO), CymaBay Therapeutics (CBAY), CrowdStrike (CRWD), GE Aerospace (GE) and Adobe (ADBE).

Company Calendar

Last Earnings
11/07/2024
Today
4/25/2025
Next Earnings (Estimated)
5/07/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Banking
Current Symbol
NASDAQ:NRBO
Employees
10
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.00
High Stock Price Target
$10.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+1,076.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-12,470,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$1.50 per share
Price / Book
0.57

Miscellaneous

Free Float
8,526,000
Market Cap
$7.32 million
Optionable
Not Optionable
Beta
-0.26
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:NRBO) was last updated on 4/26/2025 by MarketBeat.com Staff
From Our Partners